Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,098 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment.
Iacoboni G, Navarro V, Sesques P, Rejeski K, Bastos-Oreiro M, Serpenti F, Martin Lopez AA, Iraola-Truchuelo J, Delgado J, Perez A, Guerreiro M, Caballero AC, Martinez-Cibrian N, Luzardo Henriquez H, Sanchez Pina JM, Sancho JM, Ghesquieres H, Mussetti A, Lopez Corral L, Hernani R, Reguera JL, Sureda A, Bosch F, Martin Garcia-Sancho A, Kwon M, Subklewe M, Kuhnl A, Bachy E, Barba P, Villacampa G, Abrisqueta P. Iacoboni G, et al. Among authors: navarro v. J Hematol Oncol. 2024 Oct 29;17(1):102. doi: 10.1186/s13045-024-01608-8. J Hematol Oncol. 2024. PMID: 39468591 Free PMC article.
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Iacoboni G, Navarro V, Martín-López AÁ, Rejeski K, Kwon M, Jalowiec KA, Amat P, Reguera-Ortega JL, Gallur L, Blumenberg V, Gutiérrez-Herrero S, Roddie C, Benzaquén A, Delgado-Serrano J, Sánchez-Salinas MA, Bailén R, Carpio C, López-Corral L, Hernani R, Bastos M, O'Reilly M, Martín-Martín L, Subklewe M, Barba P. Iacoboni G, et al. Among authors: navarro v. J Clin Oncol. 2024 Jan 10;42(2):205-217. doi: 10.1200/JCO.23.01097. Epub 2023 Oct 24. J Clin Oncol. 2024. PMID: 37874957
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.
Iacoboni G, Iraola-Truchuelo J, O'Reilly M, Navarro V, Menne T, Kwon M, Martín-López AÁ, Chaganti S, Delgado J, Roddie C, Pérez A, Norman J, Guerreiro M, Gibb A, Caballero AC, Besley C, Martínez-Cibrián N, Mussetti A, Sanderson R, Luzardo H, Iyengar S, Sánchez JM, Jones C, Sancho JM, Barba P, Latif AL, López-Corral L, Hernani R, Reguera JL, Sureda A, Garcia-Sancho AM, Bastos M, Abrisqueta P, Kuhnl A. Iacoboni G, et al. Among authors: navarro v. Hemasphere. 2024 May 21;8(5):e62. doi: 10.1002/hem3.62. eCollection 2024 May. Hemasphere. 2024. PMID: 38774657 Free PMC article.
PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma.
Ligero M, Simó M, Carpio C, Iacoboni G, Balaguer-Montero M, Navarro V, Sánchez-Salinas MA, Bobillo S, Marín-Niebla A, Iraola-Truchuelo J, Abrisqueta P, Sala-Llonch R, Bosch F, Perez-Lopez R, Barba P. Ligero M, et al. Among authors: navarro v. EJHaem. 2023 Sep 11;4(4):1081-1088. doi: 10.1002/jha2.757. eCollection 2023 Nov. EJHaem. 2023. PMID: 38024636 Free PMC article.
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells.
Iacoboni G, Sánchez-Salinas MA, Rejeski K, Martín-López AÁ, Kwon M, Navarro V, Jalowiec KA, Hernani R, Reguera-Ortega JL, Gallur L, Blumenberg V, Herrero-García M, Roddie C, Benzaquén A, Delgado-Serrano J, Bailén R, Carpio C, Amat P, López-Corral L, Martín-Martín L, Bastos M, Subklewe M, O'Reilly M, Barba P. Iacoboni G, et al. Among authors: navarro v. Hemasphere. 2024 Jun 26;8(7):e86. doi: 10.1002/hem3.86. eCollection 2024 Jul. Hemasphere. 2024. PMID: 38948924 Free PMC article.
Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes.
Serna Á, Navarro V, Iacoboni G, López L, Sancho JM, González-Barca E, López-García A, Córdoba R, Sáez A, Ubieto AJ, Ferrero A, García T, Sánchez Á, García C, Bosch M, Cabirta A, Jiménez M, Marín-Niebla A, Bosch F, Abrisqueta P. Serna Á, et al. Among authors: navarro v. Haematologica. 2025 Jan 1;110(1):173-178. doi: 10.3324/haematol.2024.285219. Haematologica. 2025. PMID: 38988269 Free article. No abstract available.
Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms.
Jiménez M, Fernández-Naval C, Navarro V, Novoa S, Martinez-Gallo M, Medina D, Andrés C, Antón A, Peralta S, Pujadas G, Hernández C, Pagès C, Roldán E, Pumarola T, Gironella M, Ruiz-Camps I, Martínez-Gómez X, Valcárcel D, Hernández M, Bosch F, Crespo M, Esperalba J, Abrisqueta P. Jiménez M, et al. Among authors: navarro v. Am J Hematol. 2023 Aug;98(8):1204-1213. doi: 10.1002/ajh.26951. Epub 2023 May 8. Am J Hematol. 2023. PMID: 37151135 Free article.
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors.
Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay JY, Sicklick JK, Schwartz GK, Rastogi S, Jones RL, Rutkowski P, Somaiah N, Navarro V, Evans D, Trent JC. Serrano C, et al. Among authors: navarro v. Nat Med. 2023 Nov;29(11):2689-2692. doi: 10.1038/s41591-023-02578-z. Nat Med. 2023. PMID: 37828359 No abstract available.
1,098 results